Benitec Biopharma Inc. BNTC
We endeavor to become the leader in discovery, development, and commercialization of therapeutic agents capable of addressing significant unmet medical need via the application of the silence and replace approach to the treatment of genetic disorders.
Benitec Biopharma Inc. ("Benitec" or the "Company" or in the first person, "we" or "our") is a clinical-stage biotechnology company focused on the advancement of novel genetic medicines with headquarters in Hayward, California. The proprietary platform, called DNA-directed RNA interference, or ddRNAi, combines RNA interference, or RNAi, with gene therapy to create medicines that facilitate sustained silencing of disease-causing genes following a single administration. The unique therapeutic constructs also enable the simultaneous delivery of wildtype replacement genes, facilitating the proprietary "silence and replace" approach to the treatment of genetically defined diseases. We are developing a silence and replace-based therapeutic (BB-301) for the treatment of Oculopharyngeal Muscular Dystrophy (OPMD), a chronic, life-threatening genetic disorder.
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | $0 | $75.0K | $73.0K | $59.0K | $97.0K | $11.6M | — |
| R&D | $18.3M | $15.6M | $12.8M | $11.3M | $7.0M | $3.0M | $4.6M | — |
| SG&A | $23.4M | $7.0M | $6.4M | $6.6M | $6.5M | $5.6M | $4.6M | — |
| Total operating expenses | $41.8M | $22.5M | $19.2M | $17.9M | $13.7M | $8.4M | $9.6M | — |
| Operating income | -$41.8M | -$22.5M | -$19.1M | -$17.9M | -$13.6M | -$8.3M | $2.6M | — |
| Net income | -$37.9M | -$21.8M | -$19.6M | -$18.2M | -$13.9M | -$8.3M | $2.6M | — |
| EPS, basic | -1.05 | -1.22 | -14.12 | -37.88 | -3.23 | — | — | — |
| EPS, diluted | -1.05 | -1.22 | -14.12 | -37.88 | -3.23 | -8.10 | 3.05 | — |
| Shares, diluted (wtd. avg.) | 36.2M | 18.4M | 1.4M | 480,688 | 4.3M | — | — | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $97.7M | $50.9M | $2.5M | $4.1M | $19.8M | $9.8M | $15.7M | $11.9M |
| Total current assets | $98.5M | $51.7M | $3.7M | $4.8M | $20.6M | $10.8M | $18.8M | — |
| Property, plant and equipment | $131.0K | $179.0K | $87.0K | $222.0K | $375.0K | $374.0K | $470.0K | — |
| Total assets | $99.6M | $52.2M | $4.5M | $6.0M | $21.4M | $11.6M | $19.2M | — |
| Total current liabilities | $1.8M | $4.9M | $4.0M | $2.5M | $1.4M | $1.1M | $2.6M | — |
| Total liabilities | $2.3M | $5.0M | $4.3M | $3.1M | $1.4M | $1.3M | $2.6M | — |
| Retained earnings | -$228.2M | -$190.3M | -$167.9M | -$148.3M | -$130.1M | -$116.6M | -$108.9M | — |
| Total equity | $97.3M | $47.2M | $202.0K | $2.9M | $20.0M | $10.2M | $16.6M | $13.8M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$23.6M | -$19.4M | -$18.0M | -$15.9M | -$12.8M | -$7.5M | $4.8M | — |
| Depreciation and amortisation | $66.0K | $87.0K | $136.0K | $167.0K | $231.0K | $190.0K | $158.0K | — |
| Stock-based compensation | $17.4M | $830.0K | $452.0K | $870.0K | $634.0K | $237.0K | $672.0K | — |
| Capital expenditure | $18.0K | $179.0K | $1.0K | $13.0K | $221.0K | $95.0K | $404.0K | — |
| Investing cash flow | -$18.0K | -$179.0K | -$1.0K | -$13.0K | -$221.0K | -$94.0K | -$400.0K | — |
| Financing cash flow | $70.5M | $68.0M | $16.0M | — | $22.5M | $1.8M | — | — |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001193125-26-117604.
Plot the figures US dollars
- Revenue
- Gross profit
- Net income
| Fiscal year | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | $11.6M | $97.0K | $59.0K | $73.0K | $75.0K | $0 | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Net income | — | $2.6M | -$8.3M | -$13.9M | -$18.2M | -$19.6M | -$21.8M | -$37.9M |
Recent filings and events
- Officer or director change Someone at the top arrived or left. The item covers everything from a board retirement to a chief executive being removed, and only the filing itself says which. Item 5.02
- Results announced The quarterly or annual earnings release. Arrives four times a year from almost every company here. Item 2.02
- Results announced Item 2.02
- Shareholder vote The results of the annual meeting or a special vote. Item 5.07
- Results announced Item 2.02
- Material agreement signed The company entered an agreement outside the ordinary course of business - a large contract, a credit facility, a merger agreement. Item 1.01
- Other event The catch-all. The company chose to disclose something that fits no other item, so the content is whatever it says it is. Item 8.01
- Officer or director change Item 5.02
- Regulation FD disclosure Something the company told the market and had to tell everyone at once - usually a slide deck or a press release. Item 7.01
- Other event Item 8.01
- Annual report filed A new 10-K. The figures and the business description on this site come from it. Form 10-K
- Results announced Item 2.02
Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.
Others in SIC 2834
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| LLY | ELI LILLY & Co | $1.20T | 55.5x | 44.7% |
| JNJ | JOHNSON & JOHNSON | $635.76B | 23.9x | 6.0% |
| ABBV | AbbVie Inc. | $504.76B | 121.0x | 8.6% |
| MRK | Merck & Co., Inc. | $358.41B | 20.0x | 1.3% |
| ABT | ABBOTT LABORATORIES | $180.63B | 27.9x | 5.7% |
| PFE | PFIZER INC | $171.16B | 22.1x | -1.6% |
| VRTX | VERTEX PHARMACEUTICALS INC / MA | $132.80B | 34.2x | 8.9% |
| BMY | BRISTOL MYERS SQUIBB CO | $125.59B | 17.8x | -0.2% |